Pharmaceutical Product Marketing: Launching Drugs That Outperform Competition
While Megabrands are more and more an exception today and many companies invest in specialty therapeutic areas, the underlying principles of how to develop, market, sell and manage a blockbuster drug that will outperform the competition are still the same -- and are still sought after by pharmaceutical and biotech companies alike.
Best Practices, LLC's leading benchmarking report "Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters" delivers the critical building blocks essential for new product management pre and post launch. What separates industry leaders from other pharmaceutical executives is vital knowledge of when in the process to start building and where to focus resources during development - the report provides those answers.
In the benchmarking report, research analysts compile compelling metrics, best practices and lessons learned from survey responses and in-depth interviews with 24 top executives at companies such as Pfizer, Merck, Sanofi-Aventis, GlaxoSmithKline, Eli Lilly, Amgen, Boehringer-Ingelheim and Novartis.
The myriad of insights gleaned from interviewees on such topics as marketing support investment and expense patterns for high potential products will inform all marketing and branding decision-makers throughout the drug development cycle.